Chemicals
Commented by Jens Castner on October 30th, 2026 | 05:45 CET
When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates
Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.
Read
Commented by Nico Popp on October 30th, 2026 | 05:43 CET
Antimony Countdown: BASF Needs New Supplies as Perpetua Resources and NSJ Antimony Develop North American Sources
Created and published on behalf of NSJ Antimony
On November 27, 2026, China's suspension of its antimony export ban to the United States is due to expire. Without an extension by Beijing, US buyers risk losing access to this metalloid, which is essential for flame retardants and armaments. This was reported by industry publication Mining Weekly. According to market information provider Fastmarkets, antimony was trading at USD 18,300 to USD 19,000 per tonne in Rotterdam in mid-October. This is well below the all-time high of approximately USD 59,750 reached in summer 2025. However, the West's dependence on Chinese refineries remains unchanged.
Read